Immunotherapy-Chemo cocktail aims to tame stomach cancer

NCT ID NCT03813784

Completed Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants who had not received prior treatment for advanced disease. The goal is to see if this combination improves overall survival compared to chemotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab (an immunotherapy drug) combined with capecitabine and oxaliplatin (chemotherapy), followed by camrelizumab plus apatinib (a targeted therapy)
What this could lead to: If successful, this combination could offer a new first-line treatment option that helps people with advanced gastric or GEJ cancer live longer and control their disease better.
What could go wrong: This is a Phase 3 trial, but results are not yet published. The combination may cause significant side effects, and not all patients may benefit, especially those with low PD-L1 levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER GASTROESOPHAGEAL CANCER

Contacts and locations

Locations

Beijing Cancer Hospital, Peking University

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.